Acorda Therapeutics, Inc. (NASDAQ:ACOR) is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ACOR’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Acorda Therapeutics could be a solid choice for investors.
Current Quarter Estimates for ACOR
In the past 30 days, five estimates have gone higher for Acorda Therapeutics while one have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 90 cents a share 30 days ago, to $1.14 today, a move of 26.7%.
Current Year Estimates for ACOR
Meanwhile, Acorda Therapeutics’ current year figures are also looking quite promising, with the consensus estimate trend increasing from $1.42 per share 60 days ago to $1.47 per share today, an increase of 3.5%.
Acorda Therapeutics, Inc. Price and Consensus
Bottom Line
The stock has also started to move higher lately, adding 23% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report
Original post